Genetic polymorphisms of human transcription factor-7 like 2 (TCF7L2), β-defensin (DEFB1) and CD14 genes in nephrolithiasis patients
It is assumed that genetic factors play crucial role in nephrolithiasis. The present study was conducted to explore the role of Human Transcription Factor-7 like-2 (TCF7L2) β-defensin (DEFB1) and CD14 gene polymorphism in development and progression of nephrolithiasis. Methods: The genotypes of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English English |
| Published: |
Elsevier B.V.
2018
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/64936/ http://irep.iium.edu.my/64936/ http://irep.iium.edu.my/64936/ http://irep.iium.edu.my/64936/7/64936_Genetic%20polymorphisms%20of%20human%20transcription_SCOPUS.pdf http://irep.iium.edu.my/64936/13/64936_Genetic%20polymorphisms%20of%20human%20transcription.pdf |
| Summary: | It is assumed that genetic factors play crucial role in nephrolithiasis. The
present study was conducted to explore the role of Human Transcription Factor-7 like-2
(TCF7L2) β-defensin (DEFB1) and CD14 gene polymorphism in development and
progression of nephrolithiasis.
Methods: The genotypes of TCF7L2, DEFB1 and CD14 polymorphism were determined in
240 nephrolithiasis patients and 240 healthy controls by restriction digestion method of PCR.
The levels of serum TCF7L2, DEFB1, CD14, uric acid and other biochemical parameters
were measured both in nephrolithiasis patients and healthy control.
Results: The patients and control groups showed 30% and 50% 1654 AA DEFB1 genotype
respectively. The Allele frequency in case of patient’s group was 63.67% while in control
group it was 36.33%. The mean serum DEFB1 levels of the patients and control groups
attained were 115.66 and 239.43 pg/mL respectively. The allele frequency of TCF7L2 in
patients and controls were 44.17% and 70.0% for C-allele, 55.83% and 30.00% for T-allele
respectively. The mean of serum TCF7L2 levels were significantly decreased in patients
compared to control group. |
|---|